Home › Companies › IOVANCE BIOTHERAPEUTICS INC. › 2024-2025

IOVANCE BIOTHERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and IOVANCE BIOTHERAPEUTICS INC.’s Form 8-K, filed June 10, 2025 (Item 5.07 on EDGAR). Page generated October 25, 2026.

11Reported items
264Asset managers
2,301Fund votes
June 10, 2025Meeting date

Results at a glance

Meeting of June 10, 2025: 11 items on IOVANCE BIOTHERAPEUTICS INC.’s Form 8-K, filed June 10, 2025: 4 approved · 7 without a stated outcome.

Material dissent

Elect Director: Dr. Countouriotis 57% of votes cast Outcome not stated Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore IOVANCE BIOTHERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by IOVANCE BIOTHERAPEUTICS INC.

These tallies are IOVANCE BIOTHERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

IOVANCE BIOTHERAPEUTICS INC. — official shareholder meeting results, meeting held June 10, 2025
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Dr. Dukes	142,089,795	30,706,393	1,322,491	--	80,162,659	82%	Not verified	—
Elect Director: Dr. Countouriotis	97,767,917	75,070,020	1,280,742	--	80,162,659	57%	Not verified	—
Elect Director: Mr. Maynard	166,367,869	6,453,538	1,297,272	--	80,162,659	96%	Not verified	—
Elect Director: Mr. Rothbaum	166,890,379	6,038,284	1,190,016	--	80,162,659	97%	Not verified	—
Elect Director: Dr. Vogt	165,079,137	8,467,205	572,337	--	80,162,659	95%	Not verified	—
Elect Director: Dr. Weiser	165,295,535	7,540,940	1,282,204	--	80,162,659	96%	Not verified	—
Elect Director: Ms. Yarno	166,781,324	5,674,432	1,662,923	--	80,162,659	97%	Not verified	—
Proposal 2: This proposal was approved with 158,778,895 "FOR" votes, 14,490,865 "AGAINST" votes and 848,919 "ABSTAIN" votes	158,778,895	14,490,865	848,919	--	80,162,659	92%	Approved	—
Proposal 3: This proposal was approved with 248,444,246 "FOR" votes, 4,930,624 "AGAINST" votes and 906,468 "ABSTAIN" votes	248,444,246	4,930,624	906,468	--	0	98%	Approved	—
Proposal 4: This proposal was approved with 160,920,940 "FOR" votes, 12,607,644 "AGAINST" votes and 590,095 "ABSTAIN" votes	160,920,940	12,607,644	590,095	--	80,162,659	93%	Approved	—
Proposal 5: This proposal was approved with 163,851,673 "FOR" votes, 9,804,728 "AGAINST" votes and 462,278 "ABSTAIN" votes	163,851,673	9,804,728	462,278	--	80,162,659	94%	Approved	—

Source: IOVANCE BIOTHERAPEUTICS INC., Form 8-K, filed with the SEC on June 10, 2025 — read the filing on EDGAR.

How asset managers voted at the IOVANCE BIOTHERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 264 asset managers that disclosed a IOVANCE BIOTHERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of IOVANCE BIOTHERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Dr. Countouriotis

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

57% Majority: yes · of votes cast

FOR 57%AGAINST

FOR: 97,767,917AGAINST: 75,070,020

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Athena Countouriotis, M.D.

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Countouriotis”): 97,767,917 for, 75,070,020 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 57% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 6,093,079 for, 48,604,029 against, 27,255 abstained.

AGAINST

FOR: 6,093,079AGAINST: 48,604,029ABSTAIN: 27,255

Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Athena Countouriotis, M.D.” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	101	27,857,904	0	Against
BlackRock	0	7,151,892	0	Against
Delaware/Macquarie	0	4,081,508	0	Against
NORTHERN LIGHTS FUND TRUST II	3,280,195	0	0	For
T. Rowe Price	0	2,430,276	0	Against
Principal	611	2,094,700	0	Against
Charles Schwab	1,871,604	0	0	For
TIAA	0	817,117	0	Against
Equitable	0	610,583	0	Against
Fidelity	0	305,709	0	Against
Manager Directed Portfolios	302,872	0	0	For
Lincoln Financial	0	275,886	0	Against
QUANTITATIVE MASTER SERIES LLC	0	270,099	0	Against
State Street	738	269,003	0	Against
Virtus	0	177,635	0	Against
Global X	162,142	0	0	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	0	160,900	0	Against
RMB INVESTORS TRUST	0	157,696	0	Against
Guggenheim	0	150,408	0	Against
John Hancock	0	147,607	0	Against
Brighthouse	0	119,976	27,255	Mixed
Direxion Shares ETF Trust	0	145,798	0	Against
ProShares	0	145,497	0	Against
AIG/SunAmerica	0	140,283	0	Against
Aberdeen	131,800	0	0	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

2. Elect Director: Dr. Vogt

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 165,079,137AGAINST: 8,467,205

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Frederick G. Vogt, Ph.D., J.D.

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Vogt”): 165,079,137 for, 8,467,205 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 54,697,108 for, 0 against, 27,255 abstained.

FOR

FOR: 54,697,108AGAINST: 0ABSTAIN: 27,255

Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Frederick G. Vogt, Ph.D., J.D” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	27,858,005	0	For
BlackRock	7,151,892	0	For
Delaware/Macquarie	4,081,508	0	For
NORTHERN LIGHTS FUND TRUST II	3,280,195	0	For
T. Rowe Price	2,430,276	0	For
Principal	2,095,311	0	For
Charles Schwab	1,871,604	0	For
TIAA	817,117	0	For
Equitable	610,583	0	For
Fidelity	305,709	0	For
Manager Directed Portfolios	302,872	0	For
Lincoln Financial	275,886	0	For
QUANTITATIVE MASTER SERIES LLC	270,099	0	For
State Street	269,741	0	For
Virtus	177,635	0	For
Global X	162,142	0	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	160,900	0	For
RMB INVESTORS TRUST	157,696	0	For
Guggenheim	150,408	0	For
John Hancock	147,607	0	For
Brighthouse	119,976	27,255	Mixed
Direxion Shares ETF Trust	145,798	0	For
ProShares	145,497	0	For
AIG/SunAmerica	140,283	0	For
Aberdeen	131,800	0	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

3. Elect Director: Dr. Dukes

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%AGAINST

FOR: 142,089,795AGAINST: 30,706,393

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: lain Dukes, D. Phil.

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Dukes”): 142,089,795 for, 30,706,393 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 41,893,482 for, 12,803,626 against, 27,255 abstained.

FORAGAINST

FOR: 41,893,482AGAINST: 12,803,626ABSTAIN: 27,255

Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: lain Dukes, D. Phil.” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	27,855,791	2,214	0	For
BlackRock	408,187	6,743,705	0	Mixed
Delaware/Macquarie	0	4,081,508	0	Against
NORTHERN LIGHTS FUND TRUST II	3,280,195	0	0	For
T. Rowe Price	2,430,276	0	0	For
Principal	2,095,311	0	0	For
Charles Schwab	1,871,604	0	0	For
TIAA	817,117	0	0	For
Equitable	2,130	608,453	0	Against
Fidelity	211,989	93,720	0	Mixed
Manager Directed Portfolios	302,872	0	0	For
Lincoln Financial	75,186	200,700	0	Mixed
QUANTITATIVE MASTER SERIES LLC	0	270,099	0	Against
State Street	1,062	268,679	0	Against
Virtus	177,635	0	0	For
Global X	162,142	0	0	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	160,900	0	0	For
RMB INVESTORS TRUST	157,696	0	0	For
Guggenheim	150,408	0	0	For
John Hancock	147,607	0	0	For
Brighthouse	119,976	0	27,255	Mixed
Direxion Shares ETF Trust	145,798	0	0	For
ProShares	145,497	0	0	For
AIG/SunAmerica	140,283	0	0	For
Aberdeen	131,800	0	0	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

4. Elect Director: Dr. Weiser

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 165,295,535AGAINST: 7,540,940

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Michael Weiser, M.D., Ph.D.

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Weiser”): 165,295,535 for, 7,540,940 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 54,511,283 for, 185,825 against, 27,255 abstained.

FOR

FOR: 54,511,283AGAINST: 185,825ABSTAIN: 27,255

Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Michael Weiser, M.D., Ph.D.” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	27,855,791	2,214	0	For
BlackRock	7,151,892	0	0	For
Delaware/Macquarie	4,081,508	0	0	For
NORTHERN LIGHTS FUND TRUST II	3,280,195	0	0	For
T. Rowe Price	2,430,276	0	0	For
Principal	2,095,311	0	0	For
Charles Schwab	1,871,604	0	0	For
TIAA	817,117	0	0	For
Equitable	610,583	0	0	For
Fidelity	305,709	0	0	For
Manager Directed Portfolios	302,872	0	0	For
Lincoln Financial	275,886	0	0	For
QUANTITATIVE MASTER SERIES LLC	270,099	0	0	For
State Street	269,741	0	0	For
Virtus	177,635	0	0	For
Global X	162,142	0	0	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	160,900	0	0	For
RMB INVESTORS TRUST	157,696	0	0	For
Guggenheim	150,408	0	0	For
John Hancock	147,607	0	0	For
Brighthouse	119,976	0	27,255	Mixed
Direxion Shares ETF Trust	145,798	0	0	For
ProShares	145,497	0	0	For
AIG/SunAmerica	140,283	0	0	For
Aberdeen	131,800	0	0	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

5. Elect Director: Mr. Maynard

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 166,367,869AGAINST: 6,453,538

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Ryan Maynard

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Maynard”): 166,367,869 for, 6,453,538 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 63 asset managers below reported 54,542,338 for, 154,770 against, 27,255 abstained.

FOR

FOR: 54,542,338AGAINST: 154,770ABSTAIN: 27,255

Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Ryan Maynard” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	27,858,005	0	For
BlackRock	7,151,892	0	For
Delaware/Macquarie	4,081,508	0	For
NORTHERN LIGHTS FUND TRUST II	3,280,195	0	For
T. Rowe Price	2,430,276	0	For
Principal	2,095,311	0	For
Charles Schwab	1,871,604	0	For
TIAA	817,117	0	For
Equitable	610,583	0	For
Fidelity	305,709	0	For
Manager Directed Portfolios	302,872	0	For
Lincoln Financial	275,886	0	For
QUANTITATIVE MASTER SERIES LLC	270,099	0	For
State Street	269,741	0	For
Virtus	177,635	0	For
Global X	162,142	0	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	160,900	0	For
RMB INVESTORS TRUST	157,696	0	For
Guggenheim	150,408	0	For
John Hancock	147,607	0	For
Brighthouse	119,976	27,255	Mixed
Direxion Shares ETF Trust	145,798	0	For
ProShares	145,497	0	For
AIG/SunAmerica	140,283	0	For
Aberdeen	131,800	0	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

6. Elect Director: Mr. Rothbaum

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 166,890,379AGAINST: 6,038,284

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Wayne P. Rothbaum

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Rothbaum”): 166,890,379 for, 6,038,284 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 54,542,338 for, 154,770 against, 27,255 abstained.

FOR

FOR: 54,542,338AGAINST: 154,770ABSTAIN: 27,255

Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Wayne P. Rothbaum” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	27,858,005	0	For
BlackRock	7,151,892	0	For
Delaware/Macquarie	4,081,508	0	For
NORTHERN LIGHTS FUND TRUST II	3,280,195	0	For
T. Rowe Price	2,430,276	0	For
Principal	2,095,311	0	For
Charles Schwab	1,871,604	0	For
TIAA	817,117	0	For
Equitable	610,583	0	For
Fidelity	305,709	0	For
Manager Directed Portfolios	302,872	0	For
Lincoln Financial	275,886	0	For
QUANTITATIVE MASTER SERIES LLC	270,099	0	For
State Street	269,741	0	For
Virtus	177,635	0	For
Global X	162,142	0	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	160,900	0	For
RMB INVESTORS TRUST	157,696	0	For
Guggenheim	150,408	0	For
John Hancock	147,607	0	For
Brighthouse	119,976	27,255	Mixed
Direxion Shares ETF Trust	145,798	0	For
ProShares	145,497	0	For
AIG/SunAmerica	140,283	0	For
Aberdeen	131,800	0	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

7. Elect Director: Ms. Yarno

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 166,781,324AGAINST: 5,674,432

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Wendy Yarno

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Ms. Yarno”): 166,781,324 for, 5,674,432 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 63 asset managers below reported 54,697,108 for, 0 against, 27,255 abstained.

FOR

FOR: 54,697,108AGAINST: 0ABSTAIN: 27,255

Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Wendy Yarno” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	27,858,005	0	For
BlackRock	7,151,892	0	For
Delaware/Macquarie	4,081,508	0	For
NORTHERN LIGHTS FUND TRUST II	3,280,195	0	For
T. Rowe Price	2,430,276	0	For
Principal	2,095,311	0	For
Charles Schwab	1,871,604	0	For
TIAA	817,117	0	For
Equitable	610,583	0	For
Fidelity	305,709	0	For
Manager Directed Portfolios	302,872	0	For
Lincoln Financial	275,886	0	For
QUANTITATIVE MASTER SERIES LLC	270,099	0	For
State Street	269,741	0	For
Virtus	177,635	0	For
Global X	162,142	0	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	160,900	0	For
RMB INVESTORS TRUST	157,696	0	For
Guggenheim	150,408	0	For
John Hancock	147,607	0	For
Brighthouse	119,976	27,255	Mixed
Direxion Shares ETF Trust	145,798	0	For
ProShares	145,497	0	For
AIG/SunAmerica	140,283	0	For
Aberdeen	131,800	0	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

8. To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's common…

No official matchCOMPENSATION

Combines 2 wordings of this item as funds reported it.

99.8% of fund votes cast · no official result

FOR

Details: description as filed, votes by 64 asset managers

Description as filed by funds: To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder by 12,500,000 shares; and

The 64 asset managers below reported 54,619,134 for, 77,974 against, 27,255 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 54,619,134AGAINST: 77,974ABSTAIN: 27,255

Largest asset managers voting on “To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's co” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	27,858,005	0	0	For
BlackRock	7,151,892	0	0	For
Delaware/Macquarie	4,081,508	0	0	For
NORTHERN LIGHTS FUND TRUST II	3,280,195	0	0	For
T. Rowe Price	2,430,276	0	0	For
Principal	2,095,311	0	0	For
Charles Schwab	1,871,604	0	0	For
TIAA	817,117	0	0	For
Equitable	610,583	0	0	For
Fidelity	305,709	0	0	For
Manager Directed Portfolios	302,872	0	0	For
Lincoln Financial	275,886	0	0	For
QUANTITATIVE MASTER SERIES LLC	270,099	0	0	For
State Street	269,736	5	0	For
Virtus	177,635	0	0	For
Global X	162,142	0	0	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	160,900	0	0	For
RMB INVESTORS TRUST	157,696	0	0	For
Guggenheim	150,408	0	0	For
John Hancock	147,607	0	0	For
Brighthouse	119,976	0	27,255	Mixed
Direxion Shares ETF Trust	145,798	0	0	For
ProShares	145,497	0	0	For
AIG/SunAmerica	140,283	0	0	For
Aberdeen	131,800	0	0	For

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

9. TO APPROVE AN AMENDMENT TO OUR 2020 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE NUMBER OF SHARES OF THE COMPANY'S…

No official matchCOMPENSATION

99.9% of fund votes cast · no official result

FOR

Details: description as filed, votes by 64 asset managers

Description as filed by funds: TO APPROVE AN AMENDMENT TO OUR 2020 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY 1,000,000 SHARES.

The 64 asset managers below reported 54,697,108 for, 27,255 against, 0 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 54,697,108AGAINST: 27,255ABSTAIN: 0

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO OUR 2020 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE NUMBER OF SHARES OF THE COMPA” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	27,858,005	0	For
BlackRock	7,151,892	0	For
Delaware/Macquarie	4,081,508	0	For
NORTHERN LIGHTS FUND TRUST II	3,280,195	0	For
T. Rowe Price	2,430,276	0	For
Principal	2,095,311	0	For
Charles Schwab	1,871,604	0	For
TIAA	817,117	0	For
Equitable	610,583	0	For
Fidelity	305,709	0	For
Manager Directed Portfolios	302,872	0	For
Lincoln Financial	275,886	0	For
QUANTITATIVE MASTER SERIES LLC	270,099	0	For
State Street	269,741	0	For
Virtus	177,635	0	For
Global X	162,142	0	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	160,900	0	For
RMB INVESTORS TRUST	157,696	0	For
Guggenheim	150,408	0	For
John Hancock	147,607	0	For
Brighthouse	119,976	27,255	Mixed
Direxion Shares ETF Trust	145,798	0	For
ProShares	145,497	0	For
AIG/SunAmerica	140,283	0	For
Aberdeen	131,800	0	For

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

10. To approve, by non-binding advisory vote, the compensation of our named executive officers.

No official match Fund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 10 wordings of this item as funds reported it.

97% Fund and manager reports combined; may count the same shares twice · no official result

FOR

Details: votes by 263 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 63 asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers.” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	27,855,777	2,228	0	For
BlackRock	7,151,892	0	0	For
Delaware/Macquarie	4,081,508	0	0	For
NORTHERN LIGHTS FUND TRUST II	3,280,195	0	0	For
T. Rowe Price	2,430,276	0	0	For
Principal	2,095,311	0	0	For
Charles Schwab	1,871,604	0	0	For
TIAA	817,117	0	0	For
Equitable	352,793	257,790	0	Mixed
Fidelity	305,709	0	0	For
Manager Directed Portfolios	302,872	0	0	For
Lincoln Financial	275,886	0	0	For
QUANTITATIVE MASTER SERIES LLC	270,099	0	0	For
State Street	269,343	398	0	For
Virtus	177,635	0	0	For
Global X	162,142	0	0	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	160,900	0	0	For
RMB INVESTORS TRUST	157,696	0	0	For
Guggenheim	150,408	0	0	For
John Hancock	147,607	0	0	For
Brighthouse	119,976	0	27,255	Mixed
Direxion Shares ETF Trust	145,798	0	0	For
ProShares	145,497	0	0	For
AIG/SunAmerica	140,283	0	0	For
Aberdeen	0	131,800	0	Against

Fund voting reports, all 63 managers: 54,185,930 for, 511,178 against, 27,255 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 215 asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers.” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
MHR FUND MANAGEMENT LLC	24,417,103	0	For
Invenomic Capital Management LP	6,574,399	0	For
BlackRock	6,033,912	43,272	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	4,505,363	0	For
Hood River Capital Management LLC	3,914,644	0	For
T. Rowe Price	3,413,911	0	For
Palo Alto Investors LP	3,032,209	0	For
PRINCIPAL GLOBAL INVESTORS	3,010,085	0	For
State Street	2,698,874	1,058	For
Soleus Capital Management, L.P.	1,906,962	0	For
Charles Schwab	1,871,639	0	For
BANK OF AMERICA NA	1,298,111	0	For
C WorldWide Asset Management Fondsmaeglerselskab A/S	0	1,260,000	Against
Northern Trust	1,242,199	0	For
RICE HALL JAMES & ASSOCIATES, LLC	1,124,195	0	For
APIS CAPITAL ADVISORS, LLC	1,098,130	0	For
Nuveen	836,018	0	For
UBS	0	774,375	Against
Vanguard	758,768	0	For
PICTET ASSET MANAGEMENT SA	705,319	0	For
MPM BioImpact LLC	647,492	0	For
Allianz	0	606,361	Against
JACOBS LEVY EQUITY MANAGEMENT, INC	539,703	0	For
RBC Capital Markets, LLC	504,640	0	For
MELLON INVESTMENTS Corp	0	476,611	Against

Institutional-manager reports, all 215 managers: 74,550,881 for, 3,961,348 against, 161,143 abstained, 129,705 not voted. Showing the 25 largest; see all in the interactive database.

11. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year…

No official matchAUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

99.9% of fund votes cast · no official result

FOR

Details: description as filed, votes by 63 asset managers

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025;

The 63 asset managers below reported 54,697,108 for, 0 against, 27,255 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 54,697,108AGAINST: 0ABSTAIN: 27,255

Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fi” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	27,858,005	0	For
BlackRock	7,151,892	0	For
Delaware/Macquarie	4,081,508	0	For
NORTHERN LIGHTS FUND TRUST II	3,280,195	0	For
T. Rowe Price	2,430,276	0	For
Principal	2,095,311	0	For
Charles Schwab	1,871,604	0	For
TIAA	817,117	0	For
Equitable	610,583	0	For
Fidelity	305,709	0	For
Manager Directed Portfolios	302,872	0	For
Lincoln Financial	275,886	0	For
QUANTITATIVE MASTER SERIES LLC	270,099	0	For
State Street	269,741	0	For
Virtus	177,635	0	For
Global X	162,142	0	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	160,900	0	For
RMB INVESTORS TRUST	157,696	0	For
Guggenheim	150,408	0	For
John Hancock	147,607	0	For
Brighthouse	119,976	27,255	Mixed
Direxion Shares ETF Trust	145,798	0	For
ProShares	145,497	0	For
AIG/SunAmerica	140,283	0	For
Aberdeen	131,800	0	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Largest IOVANCE BIOTHERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 333,934,387 shares outstanding at the time of that meeting.

Fund voting reports: top IOVANCE BIOTHERAPEUTICS INC. shareholders by shares voted on “To approve, by non-binding advisory vote, the compensation of our named executive officers.”, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	8.34%
2	BlackRock	2.14%
3	Delaware/Macquarie	1.22%
4	NORTHERN LIGHTS FUND TRUST II	0.98%
5	T. Rowe Price	0.73%
6	Principal	0.63%
7	Charles Schwab	0.56%
8	TIAA	0.24%
9	Equitable	0.18%
10	Fidelity	0.09%

Institutional-manager reports: top IOVANCE BIOTHERAPEUTICS INC. shareholders by shares voted on “To approve, by non-binding advisory vote, the compensation of our named executive officers.”, 2024-2025
#	Asset manager	% of shares outstanding
1	MHR FUND MANAGEMENT LLC	7.31%
2	Invenomic Capital Management LP	1.97%
3	BlackRock	1.82%
4	MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	1.35%
5	Hood River Capital Management LLC	1.17%
6	T. Rowe Price	1.02%
7	Palo Alto Investors LP	0.91%
8	PRINCIPAL GLOBAL INVESTORS	0.90%
9	State Street	0.81%
10	Soleus Capital Management, L.P.	0.57%

Reported IOVANCE BIOTHERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

IOVANCE BIOTHERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
New York, NY	8.98%	DEF14A
Wayne Rothbaum	8.98%	DEF14A
Vanguard Group	8.32%	13F
BlackRock	7.28%	13F
Malvern, PA	6.83%	DEF14A
State Street	3.31%	13F
Geode Capital	1.79%	13F
Goldman Sachs	1.67%	13F
Morgan Stanley	1.20%	13F
Renaissance Technologies	1.05%	13F

Percentages above are of 333,934,387 shares outstanding, as reported by IOVANCE BIOTHERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IOVANCE BIOTHERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.

At IOVANCE BIOTHERAPEUTICS INC.'s shareholder meeting held June 10, 2025, in the 2024-2025 proxy season, 264 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,301 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. IOVANCE BIOTHERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, by non-binding advisory vote, the compensation of our named executive officers. — the reporting funds and managers cast 97% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

IOVANCE BIOTHERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.